PAN-TB Collaboration to Launch New Clinical Trial of Next-Generation Tuberculosis Treatment Regimen
Phase 2 trial will evaluate new investigational “pan-TB” regimen that includes three new compounds, in pursuit of a shorter, simpler
Phase 2 trial will evaluate new investigational “pan-TB” regimen that includes three new compounds, in pursuit of a shorter, simpler
An international conference in Almaty brought together experts from Central Asia and beyond to expand access to modern tuberculosis treatments
Seven creators from around the world will partner with TB Alliance to connect new audiences with the people and science
Carolyn Reynolds joins as Senior Vice President of External Affairs, Lynn Connolly as Chief Medical Officer, and Majda Benhayoun is
MBA students tackle one of global health’s toughest challenges – how to reduce drug rollout timelines to just one year
Findings underscore critical role of product development partnerships in delivering both innovation and access GENEVA (April 24, 2026)—A new peer-reviewed
Country-led evidence and implementation support enabled faster adoption of shorter, more effective regimens worldwide SEOUL (April 13, 2026)—A new independent
Global health leader brings deep expertise in advancing children’s health, HIV, and global health equity NEW YORK (March 2, 2026)—TB
New collaboration aims to advance innovation for a neglected and stigmatizing disease affecting hundreds of thousands worldwide NEW YORK (January
NEW YORK and MANILA, Philippines (December 19, 2025) — TB Alliance and the Asian Development Bank (ADB) have announced a